Skip to main content

Table 3 Pathologic response to NACT according to Residual Cancer Burden (RCB) scoring [10].

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Group RCB
0
n (%)
I
n (%)
II
n (%)
III
n (%)
Control n = 27 8 (29.6) 2 (7.4) 6 (22.2) 11 (40.7)
Intervention n = 25 8 (32.0) 2 (8.0) 5 (20.0) 10 (40.0)
Total n = 52 16 (30.8) 4 (7.7) 11 (21.2) 21 (40.4)
\